Product information
English summaries of Pegpesen® (inpegsomatropin injection) organized by topic: name and composition, dosing, adverse events, precautions, contraindications, pharmacology, nonclinical data, and links to trial outcomes.
Current official dossier
Official update sources now sit beside the label-style summaries
The section map below is unchanged in scope. This added dossier box directs readers to Amoytop's current product center, NMPA approval announcement, ClinicalTrials.gov registration, and PubMed-indexed publications before they enter the detailed product pages.
Section map
Name, ingredients & strengths
INN, trade name, molecular attributes, excipients, presentation forms.
Open →Dosage, missed doses & injection
Weekly dose, sites, cartridge + TopPen I pathway vs vial/syringe.
Open →Adverse events & immunogenicity
Phase II/III safety database, MedDRA summary, ADA rates vs comparator.
Open →Precautions
Full precaution topics in expandable sections for easier scanning.
Open →Contraindications
Hypersensitivity, closed epiphyses, malignancy, acute critical illness.
Open →Clinical pharmacology
Mechanism reference, pharmacodynamics, PK, interactions, overdosage.
Open →Pharmacology & toxicology
Pharmacologic effect narrative, genotoxicity, reproductive toxicity.
Open →Clinical trials (efficacy)
Registrational study design, endpoints, and outcome tables.
Open →